Search

At the beginning of the 19th century, gynaecological cancer, mainly cancer of the uterus and cervix was a dreadful, incurable affection. However, the popularization of the three fundamentals in surgery, anesthesia, asepsis and haemostasis, ushered the golden age of operative gynaecology. During that period distinguished surgeons/gynaecologists such as Friedrich Benjamin Osiander (1759-1822), Elias von Siebold (1775-1828) and Joseph-Claude-Anthelme Récamier (1774-1852) contributed to the development of the operative techniques, providing a therapeutic solution in gynaecological cancer.

In Rijeka of the 1950s professor Drago Vrbanić was well-known as an excellent gynaecologist and surgeon, especially in the field of gynaecological malignant tumours. He headed the gynaecological and radiology departments of the Sobol Brothers General Hospital, and successfully applied several radiotherapy methods. Later in the 1960s, he introduced modern classification of tumours and multidisciplinary expertise in the diagnostics and treatment of gynaecological cancers. He combined a variety of operation procedures and methods with modern radiotherapy, significantly improving the results of malignant tumour therapy.

The Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG) was organized in 1994. The GCSG has developed under the leadership of three successive group representatives, five principal study investigators, the cooperation of group members and the support of several public research funds. At present, 38 institutions are participating as active members of the GCSG of the JCOG. In addition to gynecologic oncologists, medical oncologists, pathologists and radiotherapists are participating in our group. Our group manages female genital malignancies including uterine cervical, endometrial, ovarian, tubal and vulvar cancers. Because the incidences of uterine cervical (in younger women), endometrial and ovarian cancer have increased in Japan in recent years, we are developing new standard treatments especially for these malignancies. As of 31 May 2011, our group has conducted six JCOG clinical trials (three completed and three ongoing) and completed one JCOG accompanying study, which is now in preparation for publication. Our group has also conducted several retrospective studies, and Phase I and II trials independent of the JCOG Data Center. Our aim is to conduct unique and high-quality clinical trials which we can appeal to the world. In this review, we present the organization and achievements of our group, along with a list of participating institutions, as the history of the GCSG of the JCOG.